Medical student wins essay contest forecasting healthcare’s tech-drenched future

Over the next 50 to 100 years, quantum computing will increasingly automate all manner of healthcare processes while biomaterials and genetic engineering drive regenerative medicine into everyday care.

So predicts Sam Tarassoli, a U.K. medical student whose essay on AI and the future of healthcare has taken first place in a contest across the pond sponsored by the Association of Surgeons in Training (ASiT) and Annals of Medicine and Surgery.

As part of the prize, the journal is running the essay in its May edition.

“In the next decade, the use of immersive technologies will become commonplace in and out of the surgical theatre,” writes Tarassoli, who is in his fourth year at Swansea University College of Medicine. “Use of head tracking and motion control sets would allow for greater visualization both preoperatively [and] intraoperatively.”

Moreover, with network speeds ever on the increase, “the ability to carry out procedures remotely could become an ideal of the present.”

Also in the relatively near term, Tarassoli foresees a growing role for virtual and augmented reality in guiding care and training physicians.

Further down the road, the next half century will see the continuing rise—in ways predictable and unpredictable—of AI, robotics, genomics and regenerative medicine, he writes.

“Some have theorized that artificial intelligence will be the beginning of automation in the surgical field when combined with its ability to learn and adapt to individual patients,” Tarassoli notes. “Robotic surgery is a blossoming field currently in place in theatres that will be a stalwart of the next few decades.”

Ultimately, Tarassoli concludes, the future of medicine and surgery “will depend upon the pace of medical technology development, but more importantly, the field’s specific focus on patient care. Fundamentally, these avenues will only find their long place in surgery if they address a specific clinical need while proposing themselves as an improvement to the current technique.”

The journal has posted the essay in full for free.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.